Through its diagnostic program, Biophage is developing a biosensor using an innovative nanotechnology. These nanosensors are based on impedance spectroscopy, an enabling technology that can detect and quantify microbial pathogens in real-time. The unique nanosensors will be built from various proprietary technologies already developed by Biophage (biocapture molecule: phages and antibodies) and by the Biotechnology Research Institute-NRC (signal generation and detection).
Calevia aims to harness the power of molecular targeting technologies and the heat-generation capacity of MesoGraf Xide, a photo-responsive graphene material, to create bio-conjugates designed to home-in on - and destroy - cancer cells in a non-invasive, non-pharmacological and efficient manner.
The company's lead product in development is Amorphous Nano-Hydroxyapaite Powder. Nano-structured hydroxyapatite has several advantages over hydroxyapatite of larger particle size in its use in bone tissue engineering due to its higher surface area and consequently higher reactivity, which offers better cellular response. In addition, nano-sized hydroxyapatite is useful as an effective surface modification agent for binding numerous biological molecules.
Mirexus Inc. is a natural biomaterials company that is commercializing a novel nanotechnology based on polysaccharide nanoparticles that can be used in a wide variety of markets ranging from cosmetics to nutraceuticals to biomedical applications in animal and human health. This technology was originally developed at the University of Guelph in the laboratories of Professor John Dutcher.
Nicoya is a nanotechnology company developing novel sensor products. The company's flagship product is OpenSPR - a compact, sensitive, and affordable surface plasmon resonance instrument for molecular analysis.